M&Aargenx pays $2.2B for Forte’s early autoimmune promiseBelgian-Dutch immunology company argenx has agreed to acquire Forte Biosciences for $2.2 billion (€1.9 billion), gaining FB102, an early-stage antibody that has already produced efficacy signals in … more ➔
ApprovalCHMP backs Minoryx’s rare disease drug two years after rejectionSpanish biotech Minoryx Therapeutics has secured a positive European regulatory opinion for Nezglyal, two years after regulators rejected an earlier application for the rare neurodegenerative disease … more ➔
clinical dataSanofi drops eczema drug from $1.1B Kymab dealSanofi has ended the development of amlitelimab in atopic dermatitis and will not seek regulatory approval for the drug, concluding that it would not meaningfully improve on existing treatments. more ➔
startupsIceland-based Synaptiq launches with Nobias’ rare disease drugNewly formed Synaptiq Therapeutics has acquired substantially all the assets of Nobias Therapeutics, including a clinical-stage drug whose development has already spanned several companies and more than … more ➔
Venture CapitalFresenius launches €200M healthcare venture fundGerman healthcare group Fresenius has created a corporate venture capital unit that plans to invest more than €200 million in healthcare startups over the next five years. more ➔
licensingNeurimmune turns future royalties into $425m pipeline cashSwiss biotech Neurimmune has sold part of its future royalties from its AstraZeneca-partnered experimental heart drug cliramitug to Royalty Pharma for up to $425 million, giving it fresh cash to invest … more ➔
RegulatoryOMEICOS takes repurposed drug directly into Phase 3Berlin-based OMEICOS Therapeutics can move OMT-28 directly into a pivotal Phase 3 trial in primary mitochondrial diseases after receiving supportive feedback from the U.S. Food and Drug Administration … more ➔
adobe stock photos - Michael Derrer Fuchs clinical dataNovartis drops Phase 2 radioligand therapyNovartis has discontinued development of Lu-NeoB, an experimental radioligand therapy targeting the gastrin-releasing peptide receptor, after early clinical data failed to support further developmen … more ➔
startupsImmitra Bio raises CHF 2.4M for in-vivo gene editingSwiss biotech Immitra Bio has raised CHF 2.4 million (€2.6 million) in pre-seed funding to advance an in-vivo gene editing platform initially targeting inherited blood disorders. more ➔
PhinomicsBayer Co.Lab BerlinPhinomics Brings a New Layer of Cancer Biology from the U.S. to BerlinU.S. biotech company Phinomics has established its European hub at Bayer Co.Lab Berlin, bringing a research focus that could reshape how scientists understand tumor evolution and drug resistance. The … more ➔
adobe stock photos - Michael Derrer Fuchs 
Phinomics